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INTRODUCTION 
 
 
Microalbuminuria is thought  to be a marker of wide spread vascular 
damage and also reflect the systemic trans capillary leakage of albumin. 
The significance of microalbuminuria in relation to diabetes has been 
extensively studied and documented in literature. The structural, functional and 
biochemical aspects contributing to Microalbuminuria is the basis of several 
past and ongoing studies. 
The prevalence of progression and recession of Microalbuminuria in 
various disease processes like diabetes, hypertension and coronary 
arterial  disease was repeatedly investigated in several land mark trials and have 
confirmed its investigated its significance in various studies. 
  There are few published studies on Microalbuminuria in cerebrovascular 
diseases. Observations made out of these studies confirm the relationship of 
the Microalbuminuria in cerebrovascular disease similar to those in vascular 
disorder of heart and kidney. 
Microalbuminuria reflects systemic transvascular leakiness for albumin , 
which allows higher degree of lipid insudation  into large vessel wall linking to 
atherogenesis. There is a close relation between atherosclerosis, endothelial 
dysfunction (ED) and leakage of protein through glomerulus. In endothelial 
dysfunction most effective endogeneous vasodilator nitric oxide production is 
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hampered which leads to arterial vasoconstriction. This causes increase arterial 
as well as glomerular pressure and permeability.  
In endothelial dysfunction glomerular basement membrane loses normal 
negative charges and loss of heparin like proteoglycan promoting thrombus 
formation and enhance atherosclerosis. Hence microalbuminuria is gaining 
recognition as a marker of atherogenic milieu and ischaemic stroke. 
Microalbuminuria and atherosclerosis found in endothelial dysfunction is 
manifested as increased intima media thickness of common carotid arteries .  
Microalbuminuria (MA) can be defined as urinary albumin excretion rate 
of 20-300 mg/L in spot sample or 30-300 mg/24 hrs urine collection or urine 
albumin creatinine ratio in first voided morning sample is 30-300 micro g/mg . 
In this study, microalbuminuria was defined as 20-300 mg/L. 
Microalbuminuria is also a factor that predispose hemorrhagic 
transformation of Ischemic stroke and poor outcome. 
    Hence an attempt has been made to study Microalbuminuria among 
cerebrovascular accident patients and its prognostic significance from this 
Madurai area. 
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Stroke is a major public health problem all over the world. It 
plays an important role in the morbidity and mortality in late middle age 
and in the elderly. Stroke is the third most common cause of death in the 
world after coronary artery disease and cancer. It is the single most 
important case of severe debility and also the most common life 
threatening neurological disease. 
 
The burden of stroke is likely to increase substantially in the 
future because of the aging population. Apart from employing effective 
stroke prevention programs, identification of factors associated with 
more severe stroke may help to ease the burden of this coming 
epidemic. 
 
Stroke is a heterogenous disease. Ischaemic and haemorrhagic 
strokes are the 2 main types of stroke, with very different pathogenesis 
and outcome. For India, community surveys have shown, a crude 
prevalence rate for hemiplegia is in the range of 200 per 1,00,000 
persons, nearly 1.5% of all urban hospital admission, 4.5% of all 
medical and around 20% of neurological cases. 
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AIMS AND OBJECTIVES 
 
 
 
           1.To assess the severity of  Acute Ischemic stroke in correlation with 
Micro albuminuria. 
 2.To assess the duration of presence of  microalbuminuria  after acute 
ischemic stroke. 
 3.To study the incidence of microalbuminuria in acute ischemic stroke
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REVIEW OF LITERATURE 
 
DEFINITION OF STROKE 
A stroke or CVAis a rapidly developing clinical symptoms and / or signs 
of focal and at times global   cerebral function deterioration, with symptoms 
lasting for more than 24 hours or leading to death, with no identifiable  cause 
other than that of vascular origin.  
Cerebral ischemia is  usually caused by a reduction in blood flow that 
lasts longer than several seconds. Neurologic symptoms  manifested  within 
seconds because neurons lack glycogen, so energy failure is rapid in this 
process. If the interruption of flow lasts for more  few minutes, infarction or 
death of brain tissue results 
 ANATOMY OF CEREBRAL CIRCULATION 
ARTERIES OF THE BRAIN    
 “There are Two internal carotid arteries and 2 vertebral arteries supply 
the brain and surrounding areas”.The 4 arteries lie within the substance of 
subarachnoid space and their branches joint on the inferior surface of the brain 
to form the circle of Willis. 
INTERNAL CAROTID ARTERY: 
The left common carotid artery arises  from the aorta and the right 
common carotid  arises  usuallyfrom the innominate artery. The internal 
carotid artery begins at the bifurcation of the common carotid artery. This go 
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towards the neck and perforates the base of the skull by passing through the 
carotid canal of  the temporal bone and then  continue its course. 
The artery then runs horizontally  goesforward through the cavernous 
sinus and appears  on the medial side of the anterior clinoid process and then  
by perforating the duramater. “After entering the arachnoid matter it now 
enters the subarachnoid space and goes  posteriorly to the region of the 
medial end of the lateral cerebral sulcus and split into the anterior and 
middle cerebral arteries”. 
BRANCHES OF THE CEREBRAL PORTION 
 
OPHTHALMIC ARTERY: 
 The ophthalmic artery emerges from the internal carotid artery and 
enters the orbit via  the optic canal below and lateral to the optic nerve. It 
supplies the eye and surrounding orbital structures . ‘Its terminal branches 
supply the frontal area of the scalp, the ethmoid sinus and frontal sinuses and 
the dorsum of the nose’. 
POSTERIOR COMMUNICATING ARTERY:  
“The posterior communicating artery is a small vessel that arises from 
the internal carotid artery  near  to  terminal  bifurcation  of internal carotid 
artery”.The posterior communicating artery passes posteriorly above the 
oculomotor nerve and  communicate  the posterior cerebral artery to form 
part of the circle of Willis. 
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CHOROIDAL ARTERY:  
The choroidal artery is a small branch that  runs posteriorly, close to the 
optic tract, passes the inferior horn of  lateral ventricle and terminate in the 
choroids plexus. “Choroidal artery gives off small branches to the crus 
cerebri, lateral geniculate body, optic tract and to the the internal capsule”. 
ANTERIOR CEREBRAL ARTERY: 
“It runs forward and medially and go through the longitudinal fissure of 
cerebrum superior to the optic nerve”. Here it communicate  with its fellow 
on the opposite side by means of the anterior communicating artery. It 
curves backward over the corpus callosum. The cortical branches supply the 
whole of the surface of the cerebral cortex as far back as the parieto-occipital 
sulcus. ”.  
MIDDLE CEREBRAL ARTERY: 
  It is the largest branch of the internal carotid artery, runs laterally in 
the lateral cerebral sulcus. Cortical branches supplies  the whole lateral 
surface of the hemisphere, except for the narrow strip supplied by the 
hemisphere, which are supplied by the anterior cerebral artery, the occipital 
pole and the inferolateral surface of the posterior cerebral artery.”  
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BRANCHES OF THE BASILAR ARTERY 
PONTINE ARTERIES. 
“Pontine   arteries   are   numerous  small  arteries that  enter the substance 
of the pons along the pontine surface”. 
BASILAR ARTERY 
 
The basilar artery, formed by the union of the 2 vertebral arteries, 
ascends in the groove along the anterior surface of the pons. “At the upper 
border of the pons, basilar artery split  into 2 posterior cerebral arteries”. 
 
BRANCHES OF THE BASILAR ARTERY 
 
PONTINE ARTERIES. 
 
Pontine arteries  are  numerous  small arteries that enter the substance of the 
pons. 
 
 
LABRINTHINE ARTERY 
 
Labyrinthine artery  is  a long narrow artery that supplements the 
facial and the Vestibulocochlear nerves into the internal acoustic meatus and 
supplies the internal ear. ‘It arises as a branch of the anterior inferior 
cerebellar artery’. 
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Middle Cerebral Artery Stroke 
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ANTERIOR INFERIOR CEREBELLAR ARTERY 
“AICA is the  artery passes posteriorly and laterally and supplies the 
anterior and inferior part of the cerebellum, a few branches pass through the  
pons and upper part of the medulla of the brain”. 
SUPERIOR CEREBELLAR ARTERY 
Superior cerebellar artery  arises near  to the termination  of the basilar 
artery. It wraps around the cerebral peduncle and supplies the superior 
surface of the cerebellum. “it  also supplies the pons, the pineal gland and the 
superior medullary velum of the brain”. 
POSTERIOR CEREBRAL ARTERY 
Posterior cerebral artery  curves laterally and backwards around the 
mid brain and is joined by the posterior communicating branch of the 
internal carotid artery. “Cortical branches will supply the inferolateral and 
medial surfaces of the temporal lobe and lateral and medial surfaces of the 
occipital lobe and it supplies the occipital lobe”. Central branches enters  the 
brain substance and supply palis of the thalamus, the lentiform nucleus, the 
midbrain, the pineal gland and the medial geniculate body. “A choroidal 
branch goes into the inferior horn of the lateral ventricle and supplies the 
choroid plexus”. 
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CIRCLE OF WILLS 
“The circle of Willis lies in the interpeduncular fossa at the base of the 
brain. It is formed by anastomosis between the two internal carotid arteries 
and the two vertebral arteries”. The anterior communicating, the anterior 
cerebral, internal carotid, posterior communicating, posterior cerebral, and 
the basilar arteries  they all contribute to the circle. ‘The circle of Willis 
allows blood that enters and crosses by the internal carotid or the vertebral 
arteries to be distributed to any part of either cerebral hemisphere’. The 
cortical and central branches  arises from the circle and supply the brain 
substance. 
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Posterior Circulation Stroke 
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Lacunar Stroke 
 
ARTERIES TO SPECIFIC BRAIN AREAS 
“They are the medial and lateral striate central branches of the middle 
cerebral artery supply the corpus striatum and the internal capsule; the 
central branches of the anterior cerebral artery supply the remainder of the 
structures of the brain”. 
The posterior cerebral, posterior communicating and basilar arteries 
supply the thalamus  part of the brain. 
The posterior cerebral, superior cerebellar, and basilar arteries 
supply the mid brain. 
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The basilar and anterior, inferior  branches and superior cerebellar 
arteries supply the pons of the brain’. 
The vertebral, anterior and posterior spinal, posterior inferior cerebellar and  
basilar arteries supply the medulla oblongata.  
EPIDEMIOLOGY OF CEREBROVASCULAR DISEASES IN INDIA 
The burden of stroke on the community is best reflected by its 
morbidity.Vellore was surveyed to detect cases of hemiplegia. In the second 
phase (1969 - 197 I) the population was kept under surveillance for two 
years and attempts were made to record all cases of hemiplegia. An 
incidence of 13/1,00,000 population per year was observed. The second 
study was carried out as a part of WHO collaborative study in Rohtak. 
Halyana between 1972- 1974. An annual incidence of : 34/1,00,000 
population was noted. 
In India prevalence vary from region to region. Vellore, 
Gowribidanur, and Rohtak had a prevalence of 40-60/1,00,000 population, 
whereas the Eastern part of India showed a prevalence of 100-270/1,00,000. 
Stroke incidence varies among different countries. In WHO Monica 
project has shown high prevalence and mortality among Finnish population. 
According to this study incidence of stroke varies from 106/1,00,000 in 
Germany to 290/1,00,000 population of men in Finland. 
CLASSIFICATION OF STROKE 
Stroke can be classified in various ways. Suggested classification of 
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stroke 
 
1. ANATOMICAL CLASSIFICATION. 
 
 
A. By vascular supply 
 
 
a. Carotid 
 
b. Vertebrobasilar 
 
 
B. By location 
 
 
a. Supratentorial 
 
i. Lobar 
 
ii. Ganglionic /thalamic 
 
b. lnfratentorial 
 
i. Cerebel1ar 
ii.  
 
ii. Brain stern 
 
2. ETIOLOGICAL CLASSIFICATION. 
 
A. By result. 
a. Cerebral infarct 
 
b. Cerebral haemorrhage 
  
 
i. Parenchyma 
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ii.“Subarachnoid”. 
RISK FACTORS FOR STROKE 
 
They can be grouped into modifiable and non-modifiable. Some of 
them are as follows. 
Age 
“The occurrence  of stroke increases dramatically with advancing age, 
and increasing age is an important risk factor for stroke”. 
Sex 
Male sex is linked with increased risk of stroke. 
Race 
The rate of cerebral infraction is higher in blacks than in whites. This 
could be further explained by the higher prevalence of diabetes and 
hypertension in them. 
BLOOD PRESSURE 
Hypertension is the single most important risk factor for both 
ischaemic and hemorrhagic stroke. Hypertension predisposes to ischaemic 
stroke by aggravating atherosclerosis process. In India, one ICMR 
multicentric stroke study on risk factors found hypertension, smoking, 
diabetes and low haemoglobin as risk factorsof stroke . According to them 
46% of stroke can be attributed to systolic blood pressure more than 140 mm 
of mercury. Eastern stroke and coronary heart disease collaborative research 
found that blood pressure is an important risk factor in eastern Asian 
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populations. They found that 3mm of Hg reduction in diastolic blood 
pressure should decrease the number of stroke by about a third. The SHEP 
study has shown significant reduction in non-fatal stroke events over 5 years 
in the age group 60 years and above with isolated systolic hypertension 
treated with active medication. 
Diabetes Mellitus 
“Diabetes mellitus increases the risk of cerebrovascular disease 2 – 4 
fold compared with same  risk in nondiabetics. Stroke secondary to diabetes 
may be caused by cerebrovascular atherosclerosis, cardiac embolism, and 
othrer  abnormalities”. Diabetic patients with  retinopathy and autonomic 
neuropathy are specifically  at high risk for atherosclerosis. 
Cardiovascular diseases 
“Angina or myocardial infarction is clearly associated with stroke. 
ECG abnormalities reflecting hypertension and coronary artery disease are 
risk factors for stroke. Rheumatic heart disease and cardiac failure are other 
risk factors associated with stroke”. Study on risk factors found 
hypertension, smoking, diabetes and low haemoglobin are the  risk factors. 
According to them 45% of stroke can be attributed to systolic blood pressure 
more than 140 mm of mercury. Eastern stroke and coronary heart disease 
collaborative research found that blood pressure is an significant risk factor 
in eastern Asian populations. They found that 3mm of Hg reduction in 
diastolic blood pressure should decrease the number of stroke by about a 
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third. The SHEP study has shown a 36% reduction in non-fatal stroke events 
over 5 years in the age group 60 years and above with isolated systolic 
hypertension treated with active medication. 
Claudication 
Claudication is a high risk factor for both myocardial infarction and 
stroke, presumably reflecting atheromatous disease in various part of the 
brain and vascular system. 
Cigarette smoking 
The relative risk is about 1.5. There is a dose dependent relationship 
between smoking and stroke. Cigarette smoking is important factor both in 
men and women. ICMR has shown that smoking is a risk factor both in the 
young and the elderly that predisposes to stroke. 
Atrial fibrillation 
Most frequent cardiac source of embolism to brain is atrial fibrillation 
either rheumatic or non rheumatic. Atrial fibrillation is associated with 
increased risk for stroke accounting for 5 -24 % of all ischaemic strokes and 
cause for major debility. 
Carotid artery disease 
Asymptomatic carotid artery disease less than 75% carries a stroke 
risk of 1.3% annually. With stenosis greater than 75% combined transient 
ischaemic attack and stroke rate is 10.5% per year. Carotid and 
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supraclavicular arterial bruit are strongly related to stenosis of underlying 
arteries so the examination is important. 
Transient ischemic attacks 
A TIA patient has an excess risk of stroke by about 5 - 10 times 
greater than a non TIA patient. 
Lipid abnormalities 
Increasing levels of total plasma cholesterol, LDL and decreased 
levels of HDL are strong risk factors for coronary artery disease than stroke. 
In a study conducted in NIMHANS they found that low HDL cholesterol is a 
risk factor in stroke group among various lipid fractions. Lipoprotein 'a' has 
been found to be an independent risk factor for stroke and it is a 
inflammatory marker.  
Some of the  risk factors are  Abdominal obesity, plasma fibrinogen, 
homocysteine, ‘dietary measures, snoring, cornel arcus, psychological 
factors, diagonal ear lobe crease, physical inactivity, maternal history of 
stroke, left ventricular hypertrophy’, peripheral vascular disease,  
consumption of alcohol, oral contraceptives, plasma factor seven factor 
coagulant activity, hematocrit, are some of the other risk factors of stroke. 
PATHOPHYSIOLOGY OF ACUTE ISCHEMIC STROKE: 
Cerebral infarction basically comprises two pathophysiological 
processes. 
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1. Secondary to vascular occlusion a  loss of supply of oxygen and 
glucose and  their consequences. 
2. “An array of changes in cellular metabolism consequent to the 
collapse of energy producing processes, with a disintegration of cell 
membranes and loss of function”. 
Normal cerebral blood flow at rest in normal adult brain is 
55ml/l00g/minute. When the blood flow decreases to 18ml/100g/mt brain 
reaches the threshold for electrical failure. When blood decreases to 
8ml/100g/mt cell death can result. These thresholds mark the upper and 
lower limits for the ischaemic penumbra. Ischaemic penumbra is the 
condition of the ischaemic brain between these 2 flow threshold in which 
there are some neurons that are functionally silent but are structurally intact 
and potentially salvageable and in this period intervention can be useful. 
The recognition of penumbra has focused attention on the 
development of treatment to minimize or to even reverse the damage effects 
of the ischaemic brain by drugs when started within a short period after the 
occlusion (therapeutic window). 
PET studies have detected penumbral tissues lip to 72 hours post 
stroke. It may comprise up to 50% of final volume of infarction up to 17 
hours after ischaemic insult and the out come of stroke patients depend upon 
this proportion. 
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“Ischaemia impairs cellular energy production and depletion of ATP, 
which is followed by a failure of ATP dependent ion transport system 
leading to cellular efflux of potassium and influx of sodium and water. This 
ischaemic depolarization causes presynaptic voltage sensitive calcium 
channels to open and allow calcium to enter the cell. Intracellular calcium 
stimulates neural transmitters, most notably excitatory amino acid 
glutamate”. Extra cellular glutamate then activates 2 postsynaptic receptors 
NMDA receptor and AMPA receptors. “Massive release of glutamate causes 
depolarization of adjacent neurons, triggering further neurotransmitter 
release increasing their energy requirement and tripping them into energy 
failure. This is the basis for the so-called excitotoxic cell injury”. 
Intracellular calcium triggers activation of enzymes, which affects the 
structure and function of cellular constituents and leads to damage. 
Stimulation of phospholipase leads to an inflammatory reaction through 
leucotriene production and stimulation of NO synthase, which causes build 
up of nitric oxide and free radicals which further damages the cell. 
CLINICAL FEATURES OF STROKE. 
It depends upon the site of lesion and type of stroke, ischaemic or 
hemorrhagic event. Distinction between types of stroke is possible by history 
taking physical examination and investigation. 
CLINICAL MAINFESTATIONS OF ISCHAEMIC STROKE 
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The typical  acute ischaemic stroke presents with abrupt onset of focal 
neurological deficit and is characterized  by clinically by the mode of onset 
and subsequent course of the events that takes place. 
A transient ischaemic attack is arbitrarily defined as a neurological 
deficit lasting less than 24 hours (usually 5-20 minutes). It often portends an 
impending stroke. The pathophysiological mechanisms for TIA are a low 
flow in an artery due to a tight stenosis or occlusion or an embolism. 
“A completed stroke or cerebral infarction typically evolves into 
maximum deficit in a few hours. It is sometimes heralded by TIA's. 
 In stroke in evolution the focal ischaemia worsens from minute to 
minute or hour to hour. There are usually stepwise incremental increases in 
neurological deficit occuring over several hours  after admission. The 
commonest sites of affection are 
a. The origin of the ICA within its first 2cms b. Siphon of ICA 
c. Proximal segments of MCA and ACA 
Occlusion of ICA - Patient may have amaurosis fugax before the 
occurrence of contralateral hemiparesis. 
Occlusion of MCA stem - Resulting in contralateral hemiplegia, 
hemianaesthesia and global aphasia (dominant), apraxia and anosognosia 
(nondominant hemisphere). 
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“Occlusion of inferior division MCA - Wernickes aphasia without 
weakness often with superior quadrantanopia. If nondominant hemisphere, 
hemi neglect and spatial agnosia will be seen”. 
Occlusion of ACA- Occlusion of Precommunal segment is well 
tolerated because of collateral flow. If both post communal segments arise 
from a single ACA patient suffers profound abulia (delayed motor and 
verbal response), bilateral pyramidal signs and paraplegia of the extremities. 
Occlusion of PCA- Occlusion of PCA causes serious neurological 
deficits as important structure are involved (brain stem). Thalamic 
syndrome, Thalamoperforate syndrome, Weber's syndrome are some of the 
known syndr mes of this occlusion. 
Vertebral artery and posterior inferior cerebellar artery lesions - This 
includes the well-known Lateral medullary syndrome. Medial medullary 
syndrome causes 12th nerve lesion and contra lateral hemiplegia. 
Basilar artery- Complete basilar syndrome results in bilateral long 
tract signs with variable deformities of  cerebellar, cranial nerves and other 
segmental abnormalities of brain stem. 
“Occlusion of Superior cerebellar artery - Ipsilateral cerebellar ataxia, 
contralateral hemianaesthesia, ipsilateral Horner's etc”. 
Occlusion of Anterior inferior cerebellar artery - Ipsilateral cerebellar 
ataxia, Ipsilateral Horners syndrome, conjugate gaze palsy, contra lateral loss 
of pain temperature over the body surface will be observed. 
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DIAGNOSIS OF STROKE SUBTYPE USING IMAGING 
The basic aims of imaging, in patients who have symptoms of stroke 
are 
To document the presence or absence of haemorrhage. This 
information is critical as the treatment of the two types vary. To determine 
the location and extend of brain damage and  to also  assess the current and 
impending herniation of brain. 
To exclude other entities, which may mimic stroke syndrome. To find 
out the cause of stroke. 
“Acute infarcts are more  frequently visible on MRl than on CT scans. 
On admission approximately 90% of the MRI are positive compared to 60% 
in CT scans in acute infarcts of the brain”. 
COMPUTERISED TOMOGRAPHY OF ISCHAEMIC STROKE 
 
CT radiographic images identify or exclude hemorrhage asthe cause of 
stroke, and they identify extraparenchymal hemorrhages,brain,neoplasms, 
abscesses, and other conditions mimicking as stroke.Brain CT scans 
obtained in the first several hours after an infarctiongenerally show nil 
abnormality, and the infarct may not be seen reliably for 24–48 h.  
“CT may not  show small ischemic strokes in the posterior fossa 
because of bone artifact; small infarcts on the cortical surface may also be 
undetected.The CT appearance of cerebral infarction    is time dependent. 
 26 
 
Although the findings may be detected within 6 -8 hours of onset of the 
symptoms CT may be normal up to 24 hours”. 
Hyper acute infarct (less than 12 hours) 
• Normal 55 -60% 
• “Hyper dense artery 28 -50%” 
• Obscuration of lentiform nuclei 
 Acute (12 - 24 hours) • Loss of grey white interfaces (insular ribbon 
sign, obscuration of cortex medullary white matter border) 
• “Low density basal ganglia”. 
• Sulcal effacement 
1 – 3 days 
• Increasing mass effect of brain. 
• Wedge shaped low-density area that involves both grey and    
white matter of the brain 
• Hemorrhagic transformation can  occur. 
4 - 8 days 
• “Gyral enhancement 
• Mass effect, edema persists in the brain”. 
2 - 8 weeks 
• Contrast enhancement persists. 
• Mass effect resolves 
Months to years 
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• Encephalomalacic change 
• Volume loss and 
• Rarely calcification of brain 
 
 
   As mentioned above early finding on CT may be sudden loss of grey 
White matter contrast and effacement of adjacent subarachnoid spaces of 
brain. However by 24 hours the abnormal low attenuating areas become 
obvious. Specifically insular ribbon sign has been defined as an early 
accurate sign of MCA infarction. The early findings on noncontrast CT are 
the result of development of cytotoxic edema surrounding of brain. 
Occasionally CT scan through the supra sellar cistern may show hyper dense 
MCA indicative of thrombus within the cytotoxic and vasogenic edema. 
 “Mass effect from cytotoxic edema is maximum between 3 - 10 days, 
and may lead to herniation. Mass effect I completely resolves by 3 weeks of 
duration”. 
Lacunar infarction - These are secondary to arterial disease affecting 
the deep penetrating vessels of the brain. These arteries may demonstrate 
tiny foci of stenosis caused by micro atheroma or lipohyalinosis. Because of 
the small size CT may miss the infarct of the brain. 
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TREATMENT OF ACUTE ISCHAEMIC STROKE 
 
a. Early status evaluation and supportive treatment care. 
b.” Reperfusion strategies directed at arterial recanalization” 
c. Cytoprotective strategies aimed at cellular and metabolic targets 
levels. 
Emergency care involves protection of the airway to avoid 
obstruction, hypoventilation and aspiration pneumonia. Care should be taken 
to prevent cerebral edema and those factors which exacerbate it like; 
hypoxia, hyperthermia, hypercarbia, hypovolemia, and hypertension. “If the 
patient  develops cerebral edema it should be treated with  inj mannitol 
(20%) solution Ig/kg over 30 minutes. bolus, followed by 0.25 - 0.5 gm/kg 
over 30 - 60 min every 4 - 6 hours, maintenance of euvolemia and avoidance 
of glucose containing solutions, endotracheal intubation and mechanical 
ventilation is indicated if Glasgow coma scale is <8, hyperventilating to a 
PCO2 of 30 mm of Hg if the patient has herniation of the brain”. 
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During the first few hours after the onset of symptoms of stroke, 
treatment of severe hypertension is problematic, because, a precipitous 
decline in arterial pressure maylead to  harmful decrease in local perfusion. 
There is no evidence that antihypertensive therapy is beneficial in patients 
with stroke even above the Blood Pressure treatment thresholds 
recommended by various consensus panels – systolic > 200 to 220 mm of 
Hg, diastolic >110 to 120 mm of Hg. Therapy is indicated in patients with 
stroke who have aortic dissection, acute myocardial infarction, heart failure, 
acute renal failure or hypertensive encephalopathy; and for patients receiving 
thromobolytic therapy in whom the systolic pressure is 180 mm of Hg higher 
or the diastolic pressure is 105 mm of Hg or higher. Sudden decline in 
arterial perfusion may cause harmful decrease in local perfusion 
THROMBOLYSIS 
The use of thrombolytic agents in acute cerebral infarction has been 
studied extensively in studies. Three early intravenous streptokinase trials 
were stopped because of higher death rate mainly due to intracerebral 
bleedings. 
“The European Co-operative Acute Stroke Study  tested recombinant 
tissue plasminogen activator (rtPA - 1 mg/kg to 100mg max, 10% as a bolus, 
then remainder over 60 minutes. IV) versus placebo in patients with 
ischaemic stroke within 6 hours of onset of symptom”.  
 30 
 
‘Overall thrombolysis was not beneficial because of excess of cerebral 
haemorrhage’. However in those patients who had no signs of major 
infarction on initial CT scan, the functional outcome was improved in the 
initial period. 
The National Institute of Neurological Disorder and Stroke (NINDS) 
rtPA stroke study showed a good benefit for rtPA in selected patients with 
acute stroke. ‘The NlNDS study used rtPA versus placebo in patients with 
acute ischaemic stroke within 3 hours of onset. Symptomatic intracerebral 
haemorrhage occurred in 7.5%patients on rtPA and 0.6% on placebo’. There 
was a nonsignificant reduction in mortality and a significant absolute 
increase in number of patients with only minimal disability (38% placebo vs. 
44% on rtPA). Thus despite increase in rate of ICH, treatment with IV rtPA 
within 3 hours of onset of ischaemic stroke improved clinical outcome. 
Finally ECASS II tested the NINDS dose of rtPA (0.9 mg/kg, max 
dose of 90 m) but allowed patients to receive drug up to 6th hour as in 
ECASS I. No significant benefit was found in this study. 
 “Many hospitals have developed expert stroke teams to facilitate this 
treatment of stroke. The drug is now approved in the USA and Canada for 
acute stroke within 3 hours of onset of symptoms. Two recent trials using 
intraarterial thrombolysis for acute MCA infarct showed benefit”. 
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ANTITHROMBOTIC AND ANTIPLATELET DRUGS, 
Heparin - in the international stroke trial 19,435 patients with 
ischaemic stroke were randomly assigned to receive subcutaneous herparin 
at a dose of 5,000 to 12,500 IU twice daily or no heparin, with or without 
300mg of aspirin per day, within 48 hours of onset of symptoms. There were 
no differences among the treatment groups in the primary outcome (death 
within 14 days or dependency at 6 months). Among the patients who 
received heparin, there was a significant reduction (0.9%) in the absolute 
risk of recurrent ischemic stroke during the first 14 days, an effect that was 
counter balanced by a significant increase (0.8%) in the absolute risk of 
hemorrhagic stroke. 
Kay Richard et al used low molecular weight heparin within 48 hours 
of onset of symptoms and found that there was significant improvement in 
the outcome at 6 months though others do not share this thought. A meta 
analysis of data from trials of early treatment with anticoagulant drugs for 
patients with acute ischaemic stroke suggest no clinical benefit with such 
treatment. 
Aspirin - aspirin acts by irreversible inhibition of platelet function by 
inactivation of cyclo-oxygenase enzyme International stroke trial and 
Chinese acute stroke trial showed that aspirin produces a small but real 
reduction of about 10 deaths or recurrent strokes per 1,000 during the first 
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few weeks. Both trials suggest that aspirin should be started as soon as 
possible after the onset of ischaemic stroke. 
 In the international stroke trial, secondary analysis revealed a 
significant decrease in the rate of recurrence of ischaemic stroke at two 
weeks among the patients treated with aspirin (2.8 vs. 3.9%) among those 
not treated with aspirin. However, there were no differences among the 
groups, in the combined end point of severe disability and death. Combined 
analysis of the results of the lnternational stroke trial and the Chinese acute 
stroke trial suggest that early death, recurrent stroke or late death can be 
prevented in 1 patient with acute stroke by giving aspirin to 100 patients 
with acute stroke. 
 “Cytoprotective drugs - The recognition of penumbra has focused 
attention on the development of treatment to minimize or even reverse the 
damaging effects of ischaemic brain damage and such drugs are effective 
when they are started within a short period of time after the occlusion of the 
artery (therapeutic window)”. 
Several groups of drugs have been tried. Calcium channel antagonists 
like nicardipine, nimodipine, NMDA receptor antagonists (Selfotel, 
Eliprodil), ICAM 1 antibodies , glutamate antagonist (Lebeluzole), 
GABAergic antagonist (Diazepam, Clomethiozole), free radical scavengers 
(Tirilazed, dihydrolipoate), inhibitors of lipid peroxidation (Ebselen). 
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Citicoline, intermediary in the biosynthesis of phosphatidyl choline was 
found to improve functional outcome when started within 24 hours of onset 
of stroke signs and symptoms. 
Non-pharmacological therapy – Avoidance of atheroma risk factors as 
well as life style modification is important in primary and secondary stroke 
prevention. 
Surgical therapy – Carotid atherosclerosis can be surgically  
removed(endarterectomy) or mitigated with endovascular stenting with or 
without balloon angioplasty. Anticoagulation has not been directly compared 
with antiplatelet therapy for carotid disease. 
Symptomatic carotid stenosis was studied in the North American 
Symptomatic Carotid Endarterectomy Trial (NASCET) and the European 
Carotid Surgery Trial (ECST).They showed a substantial benefit for surgery 
in patients with stenosis of ≥75%. In NASCET, the average cumulative 
ipsilateral stroke risk at 2 years was 36% for patients treated medically and 
9% for those receiving the same medical treatment plus a carotid 
endarterectomy  can be done. This 17% absolute reduction in the surgical 
group is a 65% relative risk reduction favoring surgery . NASCET also 
showed a significant, although less robust, benefit for patients with 50–70% 
stenosis. ECST found harm for patients with stenosis <30% treated 
surgically. 
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In summary, a patient with recent symptomatic hemispheric ischemia, 
high-grade stenosis in the  internal carotid artery, and an institutional 
perioperative morbidity and mortality rate of ≤6% generally should undergo 
carotid endarterectomy. If the perioperative stroke rate is >6% for any 
particular surgeon, however, the benefits of carotid endarterectomy are 
questionable. 
ENDOVASCULAR THERAPY 
Balloon angioplasty coupled with stenting is being used with 
increasing frequency to  open stenotic carotid arteries and maintain their 
patency of the artery. These techniques can treat carotid stenosis not only at 
the bifurcation but also near the skull base and in the intracranial segments. 
The Stenting and Angioplasty with Protection in Patientsat High Risk for 
Endarterectomy (SAPPHIRE) trial randomized highriskpatients with 
symptomatic carotid stenosis >50% or asymptomatic stenosis >80% to either 
stenting combined with a distal emboli-protection device or endarterectomy.  
The risk of death, stroke, or MI within 30 days and ipsilateral stroke or 
death within 1 year was 12.4% in the stenting group and 20.1% in the 
endarterectomy group (p = .055), suggesting that stenting is at the very least 
comparable to endarterectomy as a treatment option for this patient group at 
high probable risk of surgery. However, the outcomes with both 
interventions may not have been better than leaving the carotid stenoses 
 35 
 
untreated particularly for the asymptomatic patients group, and much of the 
benefit seen in the stenting group was due to a reduction in periprocedure 
MI. Two randomize trials comparing stents to endarterectomy in lowerrisk 
patients have been published. 
BYPASS SURGERY 
Extracranial-to-intracranial (EC-IC) bypass surgery has been proven 
not of benefit  for atherosclerotic stenoses that are inaccessible to 
conventional carotid endarterectomy. In patients with recent stroke, an 
associated carotid occlusion, and evidence of inadequate perfusion of the 
brain as measured with positron emission tomography, no benefit from EC-
IC bypass was found in a trial and therefore stopped. 
PROTEINURIA 
The evaluation of proteinuria is done  by dipstick  examination.The 
dipstick measurement detects only albumin and false-positive results at pH 
>7.0 or when the urine is very concentrated or contaminated with blood 
products. Because the dipstick  relies on urinary albumin concentration, a 
very dilute urine may obscure significant proteinuria on dipstick 
examination.Quantification of urinary albumin on a spot urine sample 
(ideally from a first morning void) by measurement of an albumin-to-
creatinine ratio (ACR) is helpful in approximating a 24-h albumin excretion 
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rate (AER), where ACR (mg/g) ≈AER (mg/24 h).  Proteinuria that is not 
predominantly due to albumin will be missed by dipstick screening method. 
This information is particularly important for the detection of Bence-Jones 
proteins in the urine of patients  suffering  multiple myeloma. Tests to 
measure total urine protein concentration accurately rely on precipitation 
with sulfosalicylic or trichloracetic acid . 
The magnitude of proteinuria and its composition in the urine depend 
on the mechanism of renal injury that leads to protein losses. Both charge 
and size selectivity normally prevent all plasma albumin, globulins, and  also  
other high-molecular-weight proteins from crossing the glomerular wall; 
however, if this barrier is disrupted, plasma proteins may leak into the urine 
(glomerular proteinuria; Smaller proteins (<20 kDa) are freely filtered but 
are readily reabsorbed by the proximal tubule. Traditionally, healthy 
individuals excrete <150 mg/d of total protein and <30 mg/d of albumin. 
However, even at albuminuria levels <30 mg/d, risk for progression to overt 
nephropathy or subsequent cardiovascular disease. 
The remainder of the protein in the urine is secreted by the tubules 
(Tam Horsfall, IgA, and urokinase) or represents small amounts of filtered  
microglobulin, apoproteins, enzymes, an peptide hormones. Another 
mechanism of proteinuria entails excessive production of an abnormal 
protein that exceeds the capacity of the tubule for reabsorption of proteins. 
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This situation most commonly occurs with plasma cell dyscrasias, such as 
multiple myeloma, amyloidosis, and lymphomas, that are associated with 
monoclonal production of immunoglobulin light chains . 
The normal glomerular endothelial cell forms a barrier composed of 
pores of ~100 nm that retain blood cells but offer little barrier to passage of 
most proteins. The glomerular basement membrane traps most large proteins 
(>100 kDa), and the foot processes of epithelial cells (podocytes) cover the 
urinary side of the glomerular basement membrane and produce a series of 
narrow channels (slit diaphragms) to allow molecular passage of small 
solutes and water but not proteins. Some glomerular diseases, such as 
minimal change disease, cause fusion of glomerular epithelial cell foot 
processes, resulting in predominantly “selective” loss of albumin. Other 
glomerular diseases can present with disruption of the basement membrane 
and slit diaphragms (e.g., by immune complex deposition), resulting in 
losses of albumin and other plasma proteins. The fusion of foot processes 
causes increased pressure across the capillary basement membrane, resulting 
in areas with larger pore sizes. 
When the total daily urinary excretion of protein is >3.5 g, 
hypoalbuminemia, hyperlipidemia, and edema (nephrotic syndrome;) are 
often present as well. However, total daily urinary protein excretion >3.5 g 
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can occur without the other features of the nephrotic syndrome in a variety 
of other renal diseases, including diabetes.  
Plasma cell dyscrasias (multiple myeloma) can be associated with 
large amounts of excreted light chains in the urine, which may not be 
detected by dipstick. The light chains are filtered by the glomerulus and 
overwhelm the reabsorptive capacity of the proximal tubule. Renal failure 
from these disorders occurs through a variety of mechanisms, including 
proximal tubule injury, tubule obstruction (cast nephropathy), and light chain 
deposition .  All excreted light chains are not nephrotoxic. 
Hypoalbuminemia in nephrotic syndrome occurs through excessive 
urinary losses and increased proximal tubule catabolism of filtered albumin. 
Edema forms from renal sodium retention and reduced plasma oncotic 
pressure, which favors fluid movement from capillaries to interstitium. To 
compensate for the perceived decrease in effective intravascular volume, 
activation of the renin-angiotensin system, stimulation of ADH, and 
activation of the sympathetic nervous system take place, promoting 
continued renal salt and water reabsorption and progressive edema. Despite 
these changes, hypertension is uncommon in primary kidney diseases 
resulting in the nephrotic syndrome . The urinary loss of regulatory proteins 
and changes in hepatic synthesis contribute to the other manifestations of the 
nephrotic syndrome. A hypercoagulable state may arise from urinary losses 
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of antithrombin III, reduced serum levels of proteins S and C, 
hyperfibrinogenemia, and enhanced platelet aggregation. 
Hypercholesterolemia may be severe and results from increased hepatic 
lipoprotein synthesis. Loss of immunoglobulins contributes to an increased 
risk of infection in this population. 
MICROALBUMINURIA IN ISCHEMIC STROKE: 
MA is more prevalent in patients with increased risk of vascular 
events . It predicts cardiovascular events and all-cause mortality in the 
general population and is a plausible risk factor for ischemic stroke . 
Furthermore, MA occurs transiently in acute diseases with different 
etiologies and predicts greater short- and long-term mortality in stroke 
patients . Although MA is clearly associated with clinical risk factors for 
stroke, there is little information regarding its possible role as an independent 
risk factor for stroke or as a predictor of stroke outcome. 
Slowik et al.  were the first to report a significant correlation between 
MA and severity of stroke. Beamer et al. described MA as an independent 
predictor of vascular end-point. 
Microalbuminuria signifies abnormal vascular permeability and its 
presence may be considered as kidney's notice for markedly enhanced 
cerebrovascular risk. The importance of microalbuminurea was first 
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appreciated in the early 1980s when two landmark studies in London and 
Denmark independently reported that it was predictive of development of 
overt diabetic nephropathy and progressive renal failure. 
MA is thought to be a marker of widespread vascular damage . It 
reflects the systemic transcapillary leakage of albumin , and is frequently 
accompanied by an increased activity of the von Willebrand factor and/or 
factor VII, both known to be markers of endothelial damage . 
Epidemiological studies suggest that MA can be regarded as a predictor of 
ischemic stroke in diabetic and non-diabetic subjects. The thickness of the 
intima-media complex in carotid arteries, which reflects the progression of 
atherosclerosis in these vessels, correlates 
well with the presence of MA, as shown in a study by Mykkanen et al. 
Beamer et al. have recently proved that the prevalence of microalbuminuria 
is three-fold greater in patients with recent stroke when compared to controls 
with the same profile of cardiovascular risk factors . 
Apart from the conventional risk factors for acute ischaemic stroke, 
recently MA has been found to be a potential risk factor and a predictor of 
mortality in such patients . 
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 The frequency of END differs amongst studies ranging from 12% to 
42%. In a recently published Australian study, 19% of acute stroke patients 
had END and in the Barcelona Stroke Registry, 37% showed END . The 
probable factor for this difference is that the time frame from symptoms to 
the first evaluation is varied in different studies. 
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MATERIALS AND METHODS 
STUDY POPULATION: 
SOURCE OF DATA: 
The study will be conducted on 60 stroke patients admitted to 
Government Rajaji Hospital , Madurai and they are compared with 60 age 
and sex matched controls. 
Inclusion criteria: 
All patients with clinical diagnosis of acute Ischemic stroke involving 
MCA and ACA Territory confirmed by non contrast CT scan of brain after 
excluding the patients present in exclusion criteria were included in the 
study 
Exclusion criteria: 
1.known Diabetic and Hypertensive patients, 
2.Patients without history of hypertension but with fundus changes of 
hypertensive retinopathy, 
3.Intracranial haemorrhage, 
4.Patients who are not  a known case of diabetes but with HbA1c >6.5, 
5.Patients with CKD and AKI, 
6.Patients with UTI, 
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7.Neoplasm, 
8.Females during menstrual period and pregnancy, 
9.Patients found to have macroalbuminuria at admission 
ANTI CIPATED OUTCOME: 
Presence of Microalbuminuria associated with increased severity of 
acute ischemic stroke assesed by NIHSS Stroke scale. 
 Incidence of microalbuminuria is increased in patients with acute 
ishemic stroke when compared with normal control population. 
DATA COLLECTION: 
Informed consent will be obtained from all patients to be enrolled for 
the study. In all the patients relevant information will be collected in a 
predesigned proforma. 
         The patients are selected based on clinical examinations, Non contrast 
CT scan. Data collected over a period of six months .  
LABORATORY INVESTIGATIONS 
a) Complete blood count, 
b) Renal function test, 
c) Urine routine 
d) Urine microalbuminuria 
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e)       Serum electrolyte 
f) Electrocardiogram 
g) Non contrast CT scan of Brain 
h)       FBS 
i)        Serum Lipid profile 
j)        HbA1C 
k)       Renal artery doppler 
l)     NIHSS(National Institute of Health Stroke Scale)  at admission and 
discharge 
m)     hsCRP 
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STUDY PROTOCOL: 
Patients with clinical diagnosis of acute ischemic stroke involving 
MCA and ACA territory after excluding the patients present in exclusion 
criteria confirmed  by noncontrast  CT brain were included in the study. 
       These patients were tested  for the presence of  Microalbuminuria  in 
urine within 24 hours of admission  and then one month after stroke. 
 Duration of presence of microalbuminuria after acute ishemic stroke 
was assesed after one month of stroke. 
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 Severity of stroke assessed for all the patients within 24 hours of 
admission and aftrer one month using NIHSS scale is calculated.  
DESIGN OF STUDY 
Prospective analytical study 
PERIOD OF STUDY 
March 2017 TO  August 2017 
COLLABORATING DEPARTMENTS: 
Department of general Medicine, Department of Neurology , 
Department of  Biochemistry, 
CONSENT: Individual written and informed consent. 
ANALYSIS: Statistical analysis 
CONFLICT OF INTEREST: Nil 
Method of study: 
This study was conducted in Govt. Rajaji Hospital, Madurai which is 
allied  to Madurai Medical College. This study subjects were chosen from 
the patients admitted in Department of Medicine  Govt. Rajaji Hospital 
Madurai. 
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This study was conducted in 60 patients admitted with clinical 
diagnosis of acute ischemic stroke involving MCA and ACA territory after 
excluding the patients present in exclusion criteria confirmed  by noncontrast  
CT brain were included in the study. 
       These patients were tested  for the presence of  Microalbuminuria  in 
urine within 24 hours of admission  and then one month after stroke. 
 Severity of stroke assessed for all the patients within 24 hours of 
admission and after one month using NIHSS scale. 
60 sex and age matched controls also included in the study. 
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RESULTS AND INTERPRETATION 
 
Table 1. Age distribution in cases and controls  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
0.00%
5.00%
10.00%
15.00%
20.00%
25.00%
31-40 yrs 41-50 yrs 51-60 yrs 61-70 yrs 71-80 yrs
16.70%
30.00%
18.30%
30.00%
5.00%
18.30%
25.00%
21.70%
30.00%
5.00%
Age distribution in cases and controls
cases
controls
  Age group 
  31-40 yrs 41-50 yrs 51-60 yrs 61-70 yrs 71-80 yrs 
 
Cases (N) 
10 18 11 18 3 
16.7% 30.0% 18.3% 30.0% 5.0% 
Controls 
(N) 
11 15 13 18 3 
18.3% 25.0% 21.7% 30.0% 5.0% 
Total 
21 33 24 36 6 
17.5% 27.5% 20.0% 30.0% 5.0% 
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Gender distribution in cases and controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
male female
61.70%
38.30%
55.00%
45.00%
Gender distribution in cases and controls
cases
controls
 Gender 
 male Female 
Cases(n) 37 23 
% within grp 61.7% 38.3% 
Count 33 27 
% within grp 55.0% 45.0% 
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Distribution of  spot microalbuminuria among cases and controls  
 
 
 
 
 Spot microalbuminuria Chi-Square test 
 + ve cases - ve cases p value 
Cases(n) 42 18 
0.000* 
% within grp 70.0% 30.0% 
Control 6 54 
% within grp 10.0% 90.0% 
* Significant p value 
 
 
 
 
 
 
 
 
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
90.00%
cases controls
70.00%
10.00%
30.00%
90.00%
Distribution of  spot microalbuminuria among 
cases and controls
Spot microalbuminurea  + ve
cases
Spot microalbuminurea  - ve
cases
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Distribution of One month microalbuminuria among spot 
microalbuminuria positive cases: 
 
   
One month 
microalbuminuria 
   -ve cases +ve cases 
  
cases 26 16 
% within grp 62% 38% 
 
 
 
Predisposing factors 
 
 
 H/O Smoking habit H/O alcohol habit 
 non smoker smoker 
non 
alcoholic 
Alcoholic 
cases 50 10 51 9 
% within grp 83.3% 16.7% 85.0% 15.0% 
controls 47 13 47 13 
% within grp 78.3% 21.7% 78.3% 21.7% 
P value 0.487 0.345 
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Correlation between spot Microalbuminuria and NIHSS stroke scale: 
 
 
 
 
NIHSS scale 
Spot microalbuminuria Chi-Square test 
+ ve cases -ve cases P value 
no stroke (N) 0 5 
 
 
 
 
 
 
 
0.000* 
 
% of Total .0% 8.3% 
minor stroke(N) 0 8 
% of Total .0% 13.3% 
moderate stroke(N) 0 5 
% of Total .0% 8.3% 
moderate to severe(N) 20 0 
% of Total 33.3% .0% 
severe(N) 22 0 
% of Total 36.7% .0% 
TOTAL(N) 42 18 
% of Total 70% 30.0% 
*significant p value 
 
 
 
 
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
no stroke minor
stroke
moderate
stroke
moderate
to severe
severe TOTAL
0.00% 0.00% 0.00%
33.30%
36.70%
70%
8.30%
13.30%
8.30%
0.00% 0.00%
30.00%
Correlation between microalbuminuria and NIHSS 
stroke scale:
+ ve cases
-ve cases
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Distribution of  spot microalbuminuria based on age groups: 
 
 
 
 
 
age_group Chi 
square 
test 
P value 
31-40 
yrs 
41-50 
yrs 
51-60 
yrs 
61-70 
yrs 
71-80 
yrs 
  
Positive cases 
(n) 
11 20 13 4 0 0.000* 
% 22.9% 41.7% 27.1% 8.3% .0%  
*significant p value 
 
 
 
 
 
 
0.00%
5.00%
10.00%
15.00%
20.00%
25.00%
30.00%
35.00%
40.00%
45.00%
31-40 yrs 41-50 yrs 51-60 yrs 61-70 yrs 71-80 yrs
22.90%
41.70%
27.10%
8.30%
0.00%
Distribution of  spot microalbuminuria based on age 
groups
31-40 yrs
41-50 yrs
51-60 yrs
61-70 yrs
71-80 yrs
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Distribution of  spot microalbuminuria based on gender 
 
  
Spot 
microalbuminuria 
gender P value 
   male female  
  
Positive 
cases (n) 
28 20 0.546 
% 58.3% 41.7%  
 ChiSquare test   No significant p value 
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Distribution of  spot microalbuminuria based 
on gender
male
female
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Distribution of one month NIHSS scale among study group 
 
 one month NIHS scale Frequency (n) Valid Percent 
 
no stroke 11 18.3 
minor stroke 12 20.0 
moderate stroke 18 30.0 
moderate to severe 4 6.7 
severe 15 25.0 
Total 60 100.0 
 
 
 
 
 
 
 
 
0
10
20
30
40
50
60
70
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100
18.3 20
30
6.7
25
100
Distribution of one month NIHSS scale among 
study group
no stroke
minor stroke
moderate stroke
moderate to severe
severe
Total
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Distribution of stroke type among study group 
Distribution of stroke type among study group 
 
 stroke type Frequency Valid Percent 
Valid 
ACA 28 46.7 
MCA 14 23.3 
Lac stroke 18 30.0 
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Distribution of stroke type among study 
group
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Association between one month NIHSS scale and Spot microalbuminuria in 
case group 
  
   Spot microalbuminuria 
Total 
 
NIHSS Scale1month   
- Ve 
cases 
+ ve cases P value 
 
no stroke 
 
Frequency (n) 9 2 11  
% within Spot 
microalbuminuria 
50.0% 4.8% 18.3% 
 
 
 
 
0.000* 
minor stroke 
 
Frequency (n) 8 4 12 
% within Spot 
microalbuminuria 
44.4% 9.5% 20.0% 
moderate stroke 
 
Frequency (n) 1 17 18 
Spot microalbuminuria % 5.6% 40.5% 30.0% 
moderate to severe 
Frequency (n) 0 4 4 
% within Spot 
microalbuminuria 
.0% 9.5% 6.7% 
severe 
Frequency (n) 0 15 15 
% within Spot 
microalbuminuria 
.0% 35.7% 25.0% 
Total 
Frequency (n) 18 42 60 
% within Spot 
microalbuminuria 
100.0% 100.0% 100.0% 
* Shows significant p value chi square test 
 
 
 
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
no stroke minor
stroke
moderate
stroke
moderate
to severe
severe
Association between one month NIHSS scale 
and Spot microalbuminuria in case group
 negative  cases
positive cases
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Association between stroke size  and Spot microalbuminuria in case group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
   Spot microalbuminuria 
Total 
 
 
 
P value 
   
- Ve 
cas
e 
+Ve 
cases 
strke_size 
SI 
Frequency (n) 18 2 20 
0.000* 
% within Spot 
microalbuminuria 
100.0% 4.8% 33.3% 
LI 
Frequency (n) 0 40 40 
% within Spot 
microalbuminuria 
.0% 95.2% 66.7% 
 
Total 
Frequency (n) 18 42 60 
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
90.00%
100.00%
negative cases positive cases
Association between stroke size  and Spot 
microalbuminuria in case group
small infarct
large infarct
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Association between stroke type  and Spot microalbuminuria in case group 
 
Crosstab  
   Spot microalbuminuria 
Total 
 
   
-
Ve 
cas
e 
+Ve 
cases 
P value 
type_strke 
ACA 
Frequency (n) 0 28 28  
% within Spot 
microalbuminuria 
.0% 66.7% 46.7% 
0.000* 
MCA 
Frequency (n) 0 14 14 
% within Spot 
microalbuminuria 
.0% 33.3% 23.3% 
Lac stroke 
Frequency (n) 18 0 18 
% within Spot 
microalbuminuria 
100.0% .0% 30.0% 
Total 
Frequency (n) 18 42 60 
% within Spot 
microalbuminuria 
100.0% 100.0% 100.0%  
* Shows significant p value 
chi square test 
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Association between smoking status  and Spot microalbuminuria in case 
group 
 
  
   spot_ma_cases 
Total 
 
 Smoking status -ve csses +ve cases P value 
 Non smokers Frequency (n) 16 34 50  
% within Spot 
microalbuminuria 
88.9% 81.0% 83.3% 
0.571a 
smokers Frequency (n) 2 8 10 
% within Spot 
microalbuminuria 
11.1% 19.0% 16.7% 
Total Frequency (n) 18 42 60 
% within Spot 
microalbuminuria 
100.0% 100.0% 100.0% 
a  Not significant  chi square test 
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Association between mean cholesterol and Spot microalbuminuria in case 
group 
 
 
 
N 
 
Mean 
 
Std. 
Deviati
on 
t 
Std. Error 
Mean 
 
95% Confidence 
Interval of the 
Difference 
Un 
paired 
test 
 Lower Upper P value 
Cases 60 193.35 30.842 3.865 3.982 8.291 25.709 0.000* 
controls 60 176.35 14.469 3.865 1.868 8.254 25.746  
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DISCUSSION 
 
60 cases of acute ischemic stroke within 24 hours of onset were admitted 
in the department of Medicine, Madurai Medical College and Government 
Rajaji Hospital during the period of  March 2017 to  August 2017. 
Age distribution in cases and controls: 
   In the study group,among cases 16% present between the age group of 
31 – 40yrs,30%between 41-50 yrs,18%between 
51-60yrs,18%between61-70yrs,3%between71-80yrs. 
Among controls 18%between31-40yrs,25%between41-50yrs,24%between51-
60yrs,30%between61-70yrs,5%between71-80yrs. 
Overall 17%between 31-40yrs,27%between41-50yrs,20%between51-60 
yrs,30%between61-70yrs,5%bteween71-80yrs. 
Gender distribution in cases and control: 
Among cases 61% were males,38% were females. 
Among control 55% were males,27% were females. 
Overall 55% were Males 45%females. 
Distribution of spot microalbuminuria among cases and controls: 
Among cases 70% were spot microalbuminuria positive, 
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30% were spot microalbuminuria negative. 
Among controls 10% were spot microalbuminuria negative, 
90% were spot microalbuminuria positive. 
So among cases spot microalbuminuria was significantly positive and p value is 
significant. 
Distribution of one month microalbuminuria among spot 
microalbuminuria positive cases: 
Among spot microalbuminuria positive cases one month  microalbuminuria 
positive in 38% ,negative in 62% . 
Smoking and alcohol distribution: 
Among  cases 83% were non smokers ,16% were smokers, 
Among controls 78% were non smoker. 
Among cases 85% were non alcoholic,15% were alcoholic, 
Among controls 78% were non alcoholic,21% were alcoholic. 
Correlation between spot microalbuminuria positive cases and NIHSS 
scale: 
Among  spot microalbuminuria positive cases 33% had moderate to 
severe stroke,36% had severe stroke. 
 65 
 
Among spot microalbuminuria negative cases 8.3% had no stroke,13.3% 
had minor stroke,8.3% had moderate stroke. 
Distribution of spot microalbuminuria positive cases based on age group: 
Among spot microalbuminuria positive cases 22% in 30-40yrs,41% in 
41-50 yrs ,27% in 51-60 yrs,8.3% in 61-70 yrs. 
Distribution of spot microalbuminuria positive cases based on gender: 
Among spot microalbuminuria positive cases 58% were males ,41% were 
females. 
Distribution of  one month NIHSS scale among study group: 
Among spot micro albuminuria positive cases 18% had no stroke,20% 
had minor stroke,30% had moderate stroke,6% had moderate to severe 
stroke,25% had severe stroke. 
Distribution of stroke types among study group: 
Among spot microalbuminuria positive cases 46% had ACA territory 
infarct,23% had MCA territory infarct,30% had lacunar stroke. 
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Association between one month NIHSS scale and spot microalbuminuria 
positive in case group: 
Among spot microalbuminuria  positive cases 18% had no stroke,20% 
had minor stroke ,30%  had moderate stroke,6% had moderate to severe 
stroke,25% had severe stroke.p value is significant. 
Association between stroke size and spotMA in case group: 
Among spot MA +ve cases 4.8% had small infarct,95% had large infarct.p 
value is significant. 
Among spot MA –ve cases no stroke was seen. 
Association between stroke type and spot MA : 
Among spot MA + ve cases 66% had ACA territory stroke,33% had MCA 
territory stroke. 
Among spot MA –ve cases 18% had lacunar stroke. 
Association between smoking status in  spot MA  cases: 
Among spot MA +ve cases 81% were non smokers ,19% were smokers. 
Among spot MA –ve cases 88% were non smokers ,11% were smokers. 
Association between cholesterol in cases and control: 
Among cases cholesterol value is between 193.3±30.8, 
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Among controls cholesterol value is between 176.3±14.4. 
In this study spot microalbuminuria were measured within 24 hrs of 
stroke onset and severity of stroke was also assessed at the same time using 
NIHSS scale and then microalbuminuria also measured at  the end of one month 
and severity of stroke also assessed during this time. 
 In this study majority of cases 30% are between 61-70 yrs,males are more 
than females,70% of cases were spot MA positive, one month MA was positive 
in 38% of spot MA positive cases. 
Majority of cases and control included in this study were non smokers 
and non alcoholic.In spot MA positive cases 33% had moderate to severe 
stroke,36% had severe stroke assesed by using NIHSS scale done within 24 hrs 
and 20% were present in between age 41-50 yrs and 58% were males. 
 Among spot MA positive cases 46% had ACA territotry stroke,23% had 
MCA Territory stroke and according to one month NIHSS Scale 18% had 
moderate stroke,25% had severe stroke. 
Among spot MA positive cases 95% had large infarct. 
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CONCLUSION 
 
Microalbuminuria increases the ischaemic stroke risk because of 
association between microalbuminuria with carotid intima media 
thickness and reflecting increased vascular endothelial permeability 
leading to endothelial dysfunction.  
The present study found microalbuminuria in 70% of non diabetic 
nonhypertensive ischaemic stroke and degree of MA increases with 
severity of stroke. Hence it is important to screen high risk patients for 
microalbuminuria on regular basis. Limiting urinary albumin excretion 
with angiotensin receptor inhibitor may reduce vascular events including 
stroke beyond blood pressure lowering effect. Moreover interventional 
trials are needed to establish whether the correction of increased urine 
albumin excretion rate in its own right modifies the risk of adverse 
vascular events. 
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SUMMARY 
MA is more prevalent in patients with increased risk of vascular 
events . It predicts cardiovascular events and all-cause mortality in the 
general population and is a plausible risk factor for ischemic stroke . 
Furthermore, MA occurs transiently in acute diseases with different 
etiologies and predicts greater short- and long-term mortality in stroke 
patients .  
Microalbuminuria increases the ischaemic stroke risk because of 
association between microalbuminuria with carotid intima media thickness 
and reflecting increased vascular endothelial permeability leading to 
endothelial dysfunction.  
The present study found microalbuminuria in 70% of non diabetic 
nonhypertensive acute ischaemic stroke and degree of MA increases with 
severity of stroke as assessed by NIHSS stroke scale at the time of admission 
and  after one month. When one month MA was positive it was associated 
with more severity of stroke.  
Hence it is important to screen high risk patients for microalbuminuria 
on regular basis. Limiting urinary albumin excretion with angiotensin 
receptor inhibitor may reduce vascular events including stroke beyond blood 
pressure lowering effect. Moreover interventional trials are needed to 
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establish whether the correction of increased urine albumin excretion rate in 
its own right modifies the risk of adverse vascular events. 
Presence of Microalbuminuria associated with increased severity of 
acute ischemic stroke assesed by NIHSS Stroke scale. 
 Incidence of microalbuminuria is increased in patients with 
acute ishemic stroke when compared with normal control population 
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LIMITATIONS OF STUDY 
 
1.Number  of patients included were relatively small. 
2. As the study was cross sectional in design, it is not easy to predict exactly 
whether MA preceded stroke or vice versa.  
3. Intra-individual variability in MA had to be considered. 
4.All the potential confounders of urine MA couldn’t be completely ruled out. 
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KEY TO MASTER CHART 
MA  - microalbuminuria 
NIHSS - National Institute Of Health And Stroke Scale 
P  - Present  
A  - Absent 
LI  - large Infarct 
SI  - Small Infarct 
ACA  - Anterior Cerebral artery 
MCA  - Middle Cerebral artery 
Lac   - Lacunar stroke 
Cholest - cholesterol 
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PROFORMA 
PROFORMA 
Name: 
Age / Sex: 
Occupation: 
Presenting complaints: 
Past History: 
H/o DM, HT, CKD, CAD, 
Clinical Examination: 
General Examination: 
Consciousness,  
Pallor,  
Jaundice,  
Clubbing,  
Lymphadenopathy,  
Hydration status 
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Vitals: 
PR 
BP 
RR 
SpO2 
Systemic examination: 
CVS: 
RS: 
ABDOMEN: 
CNS: 
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MASTER CHART 
age gender 
spot 
_ma 
one_ 
mth_ma 
NIHSS Scale spot NIHSS Scale one month smoking alcohol cholestrol 
strke 
size 
type 
strke 
35 m P A Moderate To Severe Stroke Moderate Stroke P P 210 L I MCA 
40 m P P Moderate To Severe Stroke Severe Stroke A A 223 L I ACA 
30 f P A Moderate To Severe Stroke Moderate Stroke A A 200 L I ACA 
48 f P A Moderate To Severe Stroke Moderate Stroke A A 186 L I ACA 
54 m P A Moderate To Severe Stroke Minor Stroke A A 211 L I ACA 
50 m P A Moderate To Severe Stroke No Stroke A A 187 L I MCA 
42 m P A Moderate To Severe Stroke Moderate Stroke A A 213 L I ACA 
62 m P P Severe Stroke Severe Stroke A A 240 L I ACA 
65 m P P Severe Stroke Severe Stroke A A 222 L I ACA 
70 m P P Severe Stroke Severe Stroke A A 198 L I ACA 
44 f P P Severe Stroke Moderate To Severe Stroke A A 199 L I MCA 
48 f P P Severe Stroke Severe Stroke A A 241 L I MCA 
69 m P A Moderate To Severe Stroke Moderate Stroke P P 222 L I ACA 
61 m P A Moderate To Severe Stroke Minor Stroke A A 231 L I ACA 
74 m P A Moderate To Severe Stroke No Stroke A A 256 L I ACA 
62 m P A Moderate To Severe Stroke Moderate Stroke A A 276 L I ACA 
43 m P A Moderate To Severe Stroke Moderate To Severe Stroke A A 200 L I MCA 
47 m P A Moderate To Severe Stroke Moderate Stroke A A 199 L I ACA 
54 m P A Moderate To Severe Stroke Moderate Stroke A A 227 L I ACA 
69 f P A Moderate To Severe Stroke Moderate Stroke A A 201 L I MCA 
73 f P P Moderate To Severe Stroke Severe Stroke P P 206 L I ACA 
30 m P P Severe Stroke Severe Stroke P P 187 L I ACA 
35 m P P Severe Stroke Severe Stroke A A 176 L I MCA 
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45 m P P Moderate To Severe Stroke Severe Stroke A A 175 L I MCA 
49 m P A Severe Stroke Moderate To Severe Stroke P P 144 SI ACA 
51 m P A Moderate To Severe Stroke Moderate Stroke A A 192 L I ACA 
61 m P A Severe Stroke Minor Stroke P P 234 L I ACA 
64 m P A Moderate To Severe Stroke Moderate Stroke A A 165 L I ACA 
66 f P A Severe Stroke Moderate Stroke A A 210 L I MCA 
39 f P A Moderate To Severe Stroke Moderate Stroke A A 160 L I ACA 
49 f P P Severe Stroke Severe Stroke A A 197 SI ACA 
51 m P P Severe Stroke Severe Stroke A A 238 L I MCA 
33 f P P Severe Stroke Severe Stroke P P 198 L I MCA 
44 f P P Severe Stroke Severe Stroke A A 168 L I ACA 
66 m P P Severe Stroke Severe Stroke A A 176 L I ACA 
39 f P P Severe Stroke Severe Stroke P P 209 L I ACA 
61 f P A Severe Stroke Moderate Stroke A A 197 L I MCA 
58 m P A Severe Stroke Moderate Stroke A A 182 L I ACA 
43 m P A Severe Stroke Minor Stroke A A 165 L I MCA 
47 f P A Severe Stroke Moderate To Severe Stroke A A 199 L I ACA 
50 m P A Severe Stroke Moderate Stroke A A 203 L I ACA 
55 f P A Severe Stroke Moderate Stroke A A 277 L I MCA 
59 m A A No Stroke No Stroke A A 188 SI lac strke 
51 f A A Minor Stroke No Stroke A A 165 SI lac strke 
59 m A A Moderate Stroke Moderate Stroke A A 155 SI lac strke 
68 f A A No Stroke No Stroke A A 160 SI lac strke 
68 m A A Minor Stroke Minor Stroke P P 159 SI lac strke 
39 m A A Moderate Stroke Minor Stroke A A 162 SI lac strke 
41 m A A No Stroke No Stroke A A 160 SI lac strke 
42 f A A Minor Stroke Minor Stroke A A 172 SI lac strke 
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49 m A A Moderate Stroke Minor Stroke A A 190 SI lac strke 
47 f A A Minor Stroke Minor Stroke A A 183 SI lac strke 
53 m A A Minor Stroke No Stroke A A 172 SI lac strke 
59 f A A Minor Stroke Minor Stroke A A 162 SI lac strke 
67 m A A Minor Stroke No Stroke A A 152 SI lac strke 
61 f A A Minor Stroke No Stroke A A 142 SI lac strke 
69 m A A No Stroke No Stroke A A 165 SI lac strke 
72 f A A No Stroke No Stroke A A 149 SI lac strke 
37 m A A Moderate Stroke Minor Stroke P A 189 SI lac strke 
67 f A A Moderate Stroke Minor Stroke A A 176 SI lac strke 
35 m A 
   
P P 188 
  
40 m A 
   
P P 176 
  
30 f A 
   
A A 184 
  
48 f A 
   
A A 176 
  
54 m A 
   
A A 192 
  
50 m A 
   
A A 180 
  
42 f A 
   
A A 176 
  
62 m A 
   
A A 165 
  
65 m A 
   
A A 176 
  
70 m A 
   
A A 183 
  
44 f P 
   
P P 177 
  
60 f P 
   
P P 166 
  
69 m A 
   
A A 174 
  
61 m A 
   
A A 162 
  
74 m A 
   
A A 172 
  
62 f A 
   
A A 158 
  
55 m A 
   
A A 167 
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33 m A 
   
A A 178 
  
54 m A 
   
A A 188 
  
69 f A 
   
P P 188 
  
73 f A 
   
P P 176 
  
30 m P 
   
A A 184 
  
35 m A 
   
A A 176 
  
45 m A 
   
A A 192 
  
49 f A 
   
P P 180 
  
40 m A 
   
A A 176 
  
61 m A 
   
A A 165 
  
64 m A 
   
A A 176 
  
66 f A 
   
A A 183 
  
39 m A 
   
A A 177 
  
49 f P 
   
A A 166 
  
51 m A 
   
A A 174 
  
55 f A 
   
P P 162 
  
44 f A 
   
P P 172 
  
66 m A 
   
A A 158 
  
39 f A 
   
A A 167 
  
61 f A 
   
A A 178 
  
58 f A 
   
A A 188 
  
43 m A 
   
A A 178 
  
49 f A 
   
A A 167 
  
50 m A 
   
P P 194 
  
55 f P 
   
A A 167 
  
59 m A 
   
A A 156 
  
51 f A 
   
A A 166 
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59 m A 
   
A A 156 
  
68 f A 
   
A A 172 
  
68 f A 
   
A A 167 
  
39 f A 
   
A A 155 
  
41 m A 
   
A A 148 
  
65 f P 
   
A A 165 
  
49 m A 
   
P P 156 
  
47 f A 
   
A A 178 
  
53 m A 
   
P P 196 
  
59 f A 
   
A A 178 
  
67 m A 
   
A A 188 
  
61 m A 
   
A A 177 
  
44 m A 
   
A A 199 
  
72 f A 
   
P P 210 
  
37 m A 
   
A A 234 
  
67 f A 
   
A A 198 
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